We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Discovery of Key Component of HIV Yields New Drug Target

Discovery of Key Component of HIV Yields New Drug Target

Discovery of Key Component of HIV Yields New Drug Target

Discovery of Key Component of HIV Yields New Drug Target

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Discovery of Key Component of HIV Yields New Drug Target"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

HIV is a retrovirus, meaning it has to copy its RNA genome into DNA in order to infect cells. Previously, it wasn’t known how the virus acquires the building blocks of genetic material it needs, called nucleotides. Importantly, it also wasn’t known how HIV does this without setting off the cells alarm systems that are poised to detect foreign DNA.

HIV is surrounded by a protein shell called the capsid. It has now been found that HIV hides within the capsid while it builds DNA. The interdisciplinary team used a hybrid approach that involved discerning the atomic structure of the capsid in different states and creating mutant versions of HIV viruses to see how this altered infection. This allowed the researchers to discover iris-like pores in the capsid that open and close like those in the eye. These pores suck in nucleotides needed for replication at great speed while keeping out any unwanted molecules. This helps to explain why HIV is so successful at evading the immune system.  

After they identified these capsid pores the team then went on to design an inhibitor molecule that could block them – hexacarboxybenzene. Once the pores were blocked by the molecule, the HIV virus was unable to copy itself and became non-infectious.

Hexacarboxybenzene cannot cross the cell membrane of human cells to gain access to the virus, but the researchers suggest that drugs could be designed in the future with similar properties but able to enter the cell. Another option is to look at drugs currently used in treating HIV, called reverse transcriptase inhibitors, to see if there are ways of improving their transit through these pores thereby enhancing their activity.

Dr Leo James at the MRC Laboratory of Molecular Biology said: “We used to think that the capsid came apart as soon as the virus entered a cell but now realise that the capsid protects the virus from our innate immune system. The channels we’ve discovered explain how the fuel for replication gets into the capsid to allow the viral genome to be made.”

Dr David Jacques at the MRC Laboratory of Molecular Biology, said: “We have already designed a prototype inhibitor that directly targets the channel. We predict that this feature may be common to other viruses and will be an attractive target for new antiviral drugs, including new treatments for HIV and related viruses.”

Dr Tim Cullingford, Programme Manager for Chemical Biology at the MRC, said: “This collaborative work between Leo James’s laboratory at the MRC Laboratory of Molecular Biology, Cambridge and Greg Towers at UCL really illustrates the value of taking an interdisciplinary approach to discovery research. The combination of atomic-level structural work with virology has enabled them to make a finding that will shape the direction of future work in this area.”